1. Baker, S. D., Khor, S. P., Adjei, A. A., Doucette, M., Spector, T., Donehower, R. C., Grochow, L. B., Sartorius, S. E., Noe, D. A., Hohneker, J. A. & Rowinsky, E. K. (1996). Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J Clin Oncol 14: 3085–3096.
2. Beuzeboc, P., Pierga, J-Y, Stoppa-Lyonnet, D., Etienne, M. C., Milano, G. & Pouillart, P. (1996). Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. Eur J Cancer 32A: 370–371.
3. Born, J., Hansen, K., Mölle, M. & Fehm, H-L (1997). Effect of sleep and circadian rhythm on human circulating immune cells. J Immunol 158: 4454–4464.
4. Chazal, M., Etienne, M. C., Renée, N., Bourgeon, A., Richelme, H. & Milano, G. (1996). Link between dihydropyrimidine dehyrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2: 507–510.
5. Daher, G. C., Naguib, F. N. M., el Kouni, M. H., Zhang, R., Soong, S. J. & Diasio, R. B. (1991). Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Biochem Pharmacol 41: 1887–1893.